0RKL Stock Overview
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr354.75 |
52 Week High | kr381.50 |
52 Week Low | kr205.50 |
Beta | 2.09 |
1 Month Change | 29.00% |
3 Month Change | 22.97% |
1 Year Change | 16.13% |
3 Year Change | 3.88% |
5 Year Change | 99.75% |
Change since IPO | 293.08% |
Recent News & Updates
Recent updates
Shareholder Returns
0RKL | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 12.1% | -1.1% | 2.2% |
1Y | 16.1% | -11.3% | 0.9% |
Return vs Industry: 0RKL exceeded the UK Medical Equipment industry which returned -11.3% over the past year.
Return vs Market: 0RKL exceeded the UK Market which returned 0.9% over the past year.
Price Volatility
0RKL volatility | |
---|---|
0RKL Average Weekly Movement | 7.5% |
Medical Equipment Industry Average Movement | 8.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RKL's share price has been volatile over the past 3 months.
Volatility Over Time: 0RKL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 160 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
Xvivo Perfusion AB (publ) Fundamentals Summary
0RKL fundamental statistics | |
---|---|
Market cap | kr11.23b |
Earnings (TTM) | kr100.43m |
Revenue (TTM) | kr642.95m |
111.8x
P/E Ratio17.5x
P/S RatioIs 0RKL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0RKL income statement (TTM) | |
---|---|
Revenue | kr642.95m |
Cost of Revenue | kr167.55m |
Gross Profit | kr475.40m |
Other Expenses | kr374.97m |
Earnings | kr100.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 12, 2024
Earnings per share (EPS) | 3.19 |
Gross Margin | 73.94% |
Net Profit Margin | 15.62% |
Debt/Equity Ratio | 0% |
How did 0RKL perform over the long term?
See historical performance and comparison